- Home
- PLRX
as 03-28-2025 4:00pm EST
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 165.5M | IPO Year: | 2020 |
| Target Price: | $9.79 | AVG Volume (30 days): | 3.4M |
| Analyst Decision: | Hold | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.26 - $16.52 | Next Earning Date: | 03-03-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 46.66% |
Stock Insider Trading Activity of Pliant Therapeutics Inc. (PLRX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Lefebvre Eric | PLRX | Chief Medical Officer | Jan 17 '25 | Sell | $11.20 | 18,478 | $206,973.93 | 194,574 | |
| Coulie Bernard | PLRX | President and CEO | Jan 17 '25 | Sell | $11.20 | 52,419 | $587,150.46 | 430,517 | |
| Ouimette Mike | PLRX | General Counsel & Corp. Sec'y | Jan 17 '25 | Sell | $11.10 | 23,500 | $261,101.08 | 80,774 | |
| Cummings Keith Lamont | PLRX | Chief Financial Officer | Jan 17 '25 | Sell | $11.20 | 20,148 | $225,679.76 | 262,608 | |
| Hull Hans | PLRX | Chief Business Officer | Jan 17 '25 | Sell | $11.20 | 15,936 | $178,500.73 | 211,558 | |
| Cheung Lily | PLRX | Chief Human Resource Officer | Jan 17 '25 | Sell | $11.20 | 3,740 | $41,892.11 | 24,550 |
Latest Pliant Therapeutics Inc. News
PLRX Breaking Stock News: Dive into PLRX Ticker-Specific Updates for Smart Investing
Zacks
2 days ago
PLRX Stock Plunges 89% in 3 Months: Here's What Investors Should Know
MT Newswires
12 days ago
Pliant Therapeutics Says Experimental Cancer Drug Shows Antitumor Activity in Phase 1 Trial
GlobeNewswire
12 days ago
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
BioPharma Dive
15 days ago
Makary advances to full senate vote; Acelyrin, Pliant adopt ‘poison pills’
MT Newswires
16 days ago
Pliant Therapeutics Signs Shareholder Rights Agreement
GlobeNewswire
16 days ago
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement
MT Newswires
25 days ago
Stifel Downgrades Pliant Therapeutics to Hold From Buy, Adjusts Price Target to $3 From $32
MT Newswires
25 days ago
Needham Downgrades Pliant Therapeutics to Hold From Buy
Compare PLRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PLRX Pliant Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.